Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P) Share Price

Price 0.375p on 18-04-2025 at 04:45:12
Change 0.00p 0%
Buy 0.40p
Sell 0.35p
Buy / Sell N4P Shares
Last Trade: Buy 1,000,000.00 at 0.3845p
Day's Volume: 0
Last Close: 0.375p
Open: 0.00p
ISIN: GB00BYW8QM32
Day's Range 0.00p - 0.00p
52wk Range: 0.375p - 0.92p
Market Capitalisation: £2m
VWAP: 0.00p
Shares in Issue: 538m

N4 Pharma Plc (N4P) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1,000,000 0.3845p Ordinary
16:05:34 - 17-Apr-25
Sell* 95,773 0.355p Ordinary
15:52:08 - 17-Apr-25
Buy* 258,517 0.3845p Ordinary
15:49:59 - 17-Apr-25
Unknown* 5,700,000 0.3505p Negotiated Trade
14:51:32 - 17-Apr-25
Unknown* 5,700,000 0.35p Negotiated Trade
14:51:21 - 17-Apr-25
Buy* 300,000 0.3855p Ordinary
13:19:08 - 17-Apr-25
Buy* 1 0.40p Ordinary
13:15:42 - 17-Apr-25
Buy* 1 0.40p Ordinary
13:13:20 - 17-Apr-25
Buy* 1 0.40p Ordinary
13:10:57 - 17-Apr-25
Buy* 1 0.40p Ordinary
13:08:35 - 17-Apr-25
See more N4 Pharma Plc trades

N4 Pharma Plc (N4P) Share Price History

Time period:
to
Date Open High Low Close Volume
18th Apr 2025 (Fri) 0.375 0.375 0.375 0.375 0
17th Apr 2025 (Thu) 0.375 0.375 0.375 0.375 13,154,317
16th Apr 2025 (Wed) 0.375 0.375 0.375 0.375 5,060,511
15th Apr 2025 (Tue) 0.375 0.375 0.375 0.375 104,270
14th Apr 2025 (Mon) 0.375 0.375 0.375 0.375 653,363
11th Apr 2025 (Fri) 0.375 0.375 0.375 0.375 1,136,335
10th Apr 2025 (Thu) 0.375 0.375 0.375 0.375 2,309,993
9th Apr 2025 (Wed) 0.425 0.425 0.375 0.375 2,154,922
8th Apr 2025 (Tue) 0.425 0.45 0.45 0.45 168,063
7th Apr 2025 (Mon) 0.425 0.425 0.425 0.425 1,435,129
4th Apr 2025 (Fri) 0.425 0.425 0.425 0.425 5,739,564
3rd Apr 2025 (Thu) 0.425 0.425 0.425 0.425 575,008
2nd Apr 2025 (Wed) 0.425 0.425 0.425 0.425 717,440
1st Apr 2025 (Tue) 0.425 0.425 0.425 0.425 1,343,768
31st Mar 2025 (Mon) 0.475 0.475 0.425 0.425 2,313,472
28th Mar 2025 (Fri) 0.475 0.475 0.475 0.475 1,513,822
27th Mar 2025 (Thu) 0.475 0.475 0.475 0.475 7,574
26th Mar 2025 (Wed) 0.475 0.475 0.475 0.475 1,800
25th Mar 2025 (Tue) 0.475 0.475 0.475 0.475 28,554
24th Mar 2025 (Mon) 0.475 0.475 0.475 0.475 411,788
21st Mar 2025 (Fri) 0.475 0.475 0.475 0.475 3,400
20th Mar 2025 (Thu) 0.475 0.46 0.46 0.46 1,969,631
19th Mar 2025 (Wed) 0.475 0.50 0.475 0.475 1,489,590
See more N4 Pharma Plc price history

N4 Pharma Plc (N4P) Regulatory News

Date Source Headline
4th Apr 2025 7:08 am RNS Posting of Circular and Notice of General Meeting
1st Apr 2025 4:08 pm RNS Placing and Subscription to raise £1,750,000
18th Feb 2025 12:34 pm RNS Holding(s) in Company
7th Feb 2025 7:00 am RNS-R Investor Webinar
27th Jan 2025 7:00 am RNS-R Investor Webinar
16th Jan 2025 7:00 am RNS-R N4 Pharma Non-Executive Director Q&A
8th Jan 2025 7:00 am RNS Directorate Changes
12th Dec 2024 7:00 am RNS N4 101 In Vitro Results
4th Dec 2024 7:00 am RNS New Patent Filing
28th Nov 2024 7:00 am RNS Grant of Options
See more N4 Pharma Plc regulatory news

N4 Pharma Plc (N4P) Share News

UK shareholder meetings calendar - next 7 days

15th Apr 2025 14:20

Read More

AIM WINNERS & LOSERS: Velocity Composites expects to beat market view

12th Dec 2024 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

AIM WINNERS & LOSERS: Biome warns on revenue; legal blow for LCM

4th Dec 2024 10:57

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More

EARNINGS: Metals One advances Black Schist, N4 generates revenue

24th Sep 2024 15:01

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec

20th Aug 2024 11:52

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More

See more N4 Pharma Plc news
FTSE 100 Latest
Value8,275.66
Change0.00

Login to your account

Forgot Password?

Not Registered